Company news

VYNE Therapeutics Inc. news in 2021

VYNE Therapeutics Inc.'s news releases, calls and decks from 2021, newest first.

View company

VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

November 9, 2021

VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021

October 27, 2021

VYNE Therapeutics Announces Formation of Scientific Advisory Board

October 20, 2021

VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

October 18, 2021

VYNE Therapeutics Announces its China Partner’s Enrollment of First Patient in Phase 3 Study of AMZEEQ® in Patients with Moderate to Severe Acne

October 4, 2021

VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases

August 11, 2021

VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited

August 11, 2021

VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone

August 1, 2021

VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021

July 26, 2021

VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne

July 18, 2021

VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

May 5, 2021

VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021

April 27, 2021

VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update

March 3, 2021

VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis

February 28, 2021

VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update

January 31, 2021

VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update

January 28, 2021

VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

January 25, 2021

VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) Company

January 20, 2021

Calls in 2021

Decks in 2021